**Caibo Shares to acquire at least 20% of peptide biotech Paitai Bio; stock surges over 60%**
Chinese medical device maker Caibo Shares (301122) signed a letter of intent to acquire at least 20% of Zhejiang Paitai Biotechnology Co., Ltd. (Paitai Bio) in cash. The deal requires Paitai Bio to first spin off its subsidiary, which recently became a major Caibo shareholder after buying 18.01% of its shares for 756 million yuan. Paitai Bio, a national-level "Little Giant" specializing in peptide cosmetics and pharmaceutical ingredients, previously withdrew a ChiNext IPO in December 2023. The transaction remains in the planning stage.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- The A-share IPO market tightened in late 2023, leading many quality companies, including Paitai Bio, to withdraw their filings.
- The semaglutide patent expiration in 2026 presents a real industrial opportunity for China's peptide sector.
- Cross-shareholding structures are used in China to align incentives across supply chains, differing from Western arm's-length transactions.
- The 60% stock surge reflects market optimism, though its basis in fundamentals versus speculation is debated.
Points of contention
- Eastern Agent sees the circular ownership as strategic alignment, while Neutral Agent views it as a conflict of interest that obscures fair valuation.
- Neutral Agent demands audited financials and independent valuation before judging the deal, but Eastern Agent argues such transparency is unrealistic before closing and reflects Western bias.
- Eastern Agent frames the IPO withdrawal as a strategic pivot due to market conditions, while Neutral Agent questions the lack of public financial data since 2022.
- Neutral Agent insists the price of the stake is the core issue, but Eastern Agent argues the partnership structure and long-term synergies matter more than a single number.
Blind spots
- Both sides overlook how minority shareholders in Caibon are affected by the 60% stock surge and potential price mismatch with the subsidiary's earlier investment.
- The debate assumes the CSRC will adequately review the deal, but doesn't address past regulatory failures in similar structures.
- Neither side fully explores alternative partnership models that could achieve GLP-1 goals without circular ownership risks.
WorldAttention’s read
This debate highlights a clash between two views of corporate governance: one that trusts strategic cross-shareholding to build long-term industrial partnerships, and another that demands transparent pricing and audited financials to protect investors. While both agree the GLP-1 opportunity is real and the IPO market was tight, they split on whether the circular ownership structure is a smart alignment tool or a red flag. The key blind spot is the impact on minority shareholders and the lack of independent scrutiny. Ultimately, the deal's legitimacy hinges on the undisclosed price and financial data—until those are public, the stock surge remains a speculative bet, not a proven thesis.
Reporting timeline
CaiNa Shares Surges Over 60% as It Plans to Acquire Stake in Peptide Biotech Firm
CaiNa Shares (stock code 301122), a Chinese medical device maker, announced it has signed a letter of intent to acquire at least 20% of Zhejiang Paitai Biotechnology Co., Ltd. (Paitai Bio) in cash. The deal, which is not expected to constitute a major asset重组, involves seven sellers including Xinghai Ying and Shengzhou Hanyuan Investment. The acquisition price and final ratio are subject to due diligence and valuation. A key condition is the spin-off of Paitai Bio's wholly-owned subsidiary, Zhejiang Paitai Medical Industry Co., Ltd. (Paitai Medical), which recently became a major shareholder of CaiNa Shares after acquiring 18.01% of its stock for 756 million yuan in July 2025. Paitai Bio, a national-level 'Little Giant' specialized in peptide cosmetics and pharmaceutical ingredients, counts Huaren Shuanghe, Huaxi Bio, and Proya among its clients. It previously filed for a ChiNext IPO in June 2023 seeking to raise 1.245 billion yuan but withdrew in December 2023. CaiNa Shares stated the acquisition aims to integrate high-quality resources and enhance its competitive edge in the health industry, while continuing to develop its core injection device business.
Read sourceCaijun Medical Plans to Acquire Stake in Peptide Biotech; Stock Surges Over 60%
Caijun Medical (stock code 301122) announced a plan to acquire at least 20% of Zhejiang Paitai Biotechnology Co., Ltd. (Paitai Bio) in cash. The stock has surged over 60% since September. The deal is expected not to constitute a major asset重组. A key condition is the spin-off of Paitai Bio's subsidiary, Paitai Medical, which recently became a major shareholder of Caijun Medical by acquiring 18.01% of its shares. Paitai Bio, a national 'Little Giant' firm specializing in peptide cosmetics and pharmaceutical ingredients, counts Huaren Shuanghe, Bloomage Biotechnology, and Xiansheng Pharma among its clients. It previously filed for an IPO on the ChiNext board in 2023 but withdrew in December. Caijun Medical, a leading injection device maker, stated the acquisition aims to build a new profit growth point in the health sector and achieve synergies. CICC forecasts that demand for peptide APIs will accelerate due to the expiration of semaglutide's core patent in China in March 2026. The transaction is still in the planning stage and subject to uncertainty.
Caibon Shares Plans to Acquire Peptide Biotech; Stock Surges on News
Caibon Shares (stock code 301122) announced it has signed a letter of intent to acquire Zhejiang Paitai Biotechnology Co., Ltd. (Paitai Biotech) in a cash deal from seven sellers including Xinghai Ying and Shengzhou Hanyuan Investment Management Partnership. A key condition is the prior spin-off of Paitai Biotech's subsidiary, Zhejiang Paitai Pharmaceutical Industry Co., which recently became a major Caibon shareholder by acquiring 18.01% of its shares for 756 million yuan. Paitai Biotech, a national-level specialized and new 'little giant' enterprise founded in 2015, supplies peptide raw materials to cosmetics and pharmaceutical firms including Proya, Huaxi Bio, Huarun Shuanghe, and Xiansheng Pharma. Huarun Shuanghe holds 25.29% as the largest shareholder, with Xinghai Ying as the actual controller. Paitai Biotech had filed for an IPO on the ChiNext board in June 2023, aiming to raise 1.245 billion yuan, but withdrew in December 2023 without public explanation. The company's revenue grew from 86.17 million yuan in 2020 to 215 million yuan in 2022. Caibon Shares, a medical device maker, stated the acquisition would help integrate high-quality resources and create synergies in the health industry. The deal comes as demand for peptide active pharmaceutical ingredients is expected to rise following the patent expiry of semaglutide in China in March 2026. CICC noted a supply shortage for high-quality peptide API capacity. The transaction remains in the planning stage and carries uncertainty.
Read sourceShow 2 older updatesHide older updates
Caibon Shares Plans to Acquire Stake in Peptide Firm, Stock Surges Over 60%
Caibon Shares (301122) announced a plan to acquire at least a 20% stake in Zhejiang Paitide Biotechnology Co., Ltd. (Paitide Bio) via cash payment, signing a letter of intent with seven transferors including Xing Haiying and Shengzhou Hanyuan Investment Management Partnership. The deal, which is not expected to constitute a major asset重组, is subject to due diligence and valuation, with an exclusivity period until March 31, 2027. A key condition is the spin-off of Paitide Bio's subsidiary, Zhejiang Paitide Pharmaceutical Industry Co., Ltd., which recently became a major shareholder of Caibon Shares after acquiring 18.01% of its stock in September. Paitide Bio, a national-level 'Little Giant' firm specializing in peptide cosmetics and pharmaceuticals, counts clients like Proya, Bloomage Biotechnology, China Resources Double-Crane, and Simeere Pharmaceutical. It previously filed for a ChiNext IPO in June 2023 but withdrew in December 2023. Caibon Shares, a medical device maker, sees this as a move to expand in the health sector and create synergies with its injection and puncture device business. The acquisition is in early stages and carries uncertainty. The stock has risen over 60% since September. Analysts at CICC note that demand for peptide APIs is accelerating due to the upcoming patent expiration of semaglutide in China in March 2026.
Read sourceCaibo Shares Plans Stake Acquisition in Peptide Firm; Stock Surges Over 60% Since September
Caibo Shares (301122) announced plans to acquire at least 20% of Zhejiang Paitai Biotechnology Co., Ltd. (Paitai Bio) via cash payment, signing a letter of intent with seven transferors including Xing Haiying and Shengzhou Hanyuan Investment Management Partnership. The deal, subject to due diligence and valuation, requires Paitai Bio's subsidiary Zhejiang Paitai Pharmaceutical Industry Co., Ltd. to be spun off first. Paitai Bio, a national-level specialized 'Little Giant' enterprise, focuses on peptide cosmetic raw materials and peptide pharmaceuticals, serving clients like Proya, Huaxi Bio, China Resources Double-Crane, and Xiansheng Pharma. It previously filed for a ChiNext IPO in June 2023 but withdrew in December 2023. Caibo Shares, a leading domestic injection and puncture device maker, reported 2025 revenue of 357 million yuan and net profit of 5.62 million yuan. The company aims to expand in the health sector through M&A. CICC notes that GLP-1 drug demand, driven by the expiration of semaglutide's core compound patent in China in March 2026, is boosting peptide API demand, potentially creating synergies with Caibo's existing business. The transaction remains in the planning stage with uncertainties.
Read source